# Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

> **NCT04782895** · PHASE3 · COMPLETED · sponsor: **Xiamen University** · enrollment: 488 (actual)

## Conditions studied

- Cervical Cancer
- Condylomata Acuminata

## Interventions

- **BIOLOGICAL:** Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- **BIOLOGICAL:** Gardasil®9

## Key facts

- **NCT ID:** NCT04782895
- **Lead sponsor:** Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-14
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-07-25
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04782895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04782895, "Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04782895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*